Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

INDUSTRY 5 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 4 Colorectal Neoplasms 3 Triple Negative Breast Neoplasms 2 Neoplasm Metastasis 2 Stomach Neoplasms 1 Sarcoma 1 Rectal Neoplasms 1 Pathologic Complete Response 1 Neoplasms 1 Muscle Invasive Bladder Cancer (MIBC) 1 Hemangiosarcoma 1 Head and Neck Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 200 Capecitabine 116 S 1 (combination) 106 Fluorouracil 105 Docetaxel 100 Cisplatin 88 Leucovorin 75 Paclitaxel 71 Irinotecan 68 apatinib 43 sintilimab 42 Drug Therapy 42 Surgical Procedures, Operative 37 Hyperthermic Intraperitoneal Chemotherapy 34 pembrolizumab 32 Radiotherapy 31 Trastuzumab 30 Gastrectomy 23 Nivolumab 22 Epirubicin 22 Tegafur 21 Bevacizumab 21 XELOX 20 titanium silicide 19 camrelizumab 19 tislelizumab 17 Ramucirumab 17 Carboplatin 16 Neoadjuvant Therapy 15 Endoscopic Mucosal Resection 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Stomach Neoplasms × zanidatamab × Clear all

NCT07176312 2026-02-04

ZANGEA

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Recruiting

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡